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Abstract: A large number of Epstein Barr virus (EBV) immortalized lymphoblastoid cell lines (LCLs) have been generated and maintained in genetic/epidemiological studies as a perpetual source of DNA and as a surrogate in vitro
cell model. Recent successes in reprograming LCLs into induced pluripotent stem cells (iPSCs) has paved the way
to generate more relevant in vitro disease models using this existing bioresource. However, the latent EBV infection
in the LCLs make them a unique cell type by altering expression of many cellular genes and miRNAs. These EBV induced changes in the LCL miRNome and transcriptome are reversed upon reprogramming into iPSCs, which allows
a unique opportunity to better understand the miRNA and mRNA interactions that are EBV induced in LCLs and the
changes that takes place during iPSC reprogramming. To identify the potential miRNA-mRNA interactions and better
understand their role in regulating the cellular transitions in LCLs and their reprogrammed iPSCs, we performed a
parallel genome-wide miRNA and mRNA expression analysis in six LCLs and their reprogrammed iPSCs. A total of 85
miRNAs and 5,228 mRNAs were significantly differentially expressed (DE). The target prediction of the DE miRNAs
using TargetScan-Human, TarBase and miRecords databases identified 1,842 mRNA targets that were DE between
LCLs and their reprogrammed iPSCs. The functional annotation, upstream regulator and gene expression analysis
of the predicted DE mRNA targets suggest the role of DE miRNAs in regulating EBV induced changes in LCLs and
self-renewal, pluripotency and differentiation in iPSCs.
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Introduction
Induced pluripotent stem cells (iPSCs) reprogrammed from cryopreserved lymphoblastoid
cell lines (LCLs), represent a uniquely valuable
resource for biomedical research in disease
modeling, disease gene identification and for
screening new therapeutics, because LCLs collected in genetic and epidemiological studies
represents one of the largest, well-characterized, existing bioresources available for iPSC
reprogramming. Furthermore, a multitude of
phenotypic , genotypic and omics data already
exists on their donors [1].
Over the last few years, the reprogramming
methodology of cryopreserved LCLs has
improved significantly [2]. In our own work, we
have a 100% success rate and a very high

reprogramming efficiency in reprogramming
cryopreserved LCLs from more than 150 participants of our San Antonio Family Heart Study
(SAFHS). We have also published a detailed
account of miRNAs and mRNAs that are differentially expressed during iPSC reprogramming
of cryopreserved LCLs [2].
However, the latent Epstein Barr virus (EBV)
infection in the LCLs make them a unique cell
type compared to a more conventionally used
dermal fibroblast or other primary cells. In LCLs,
EBV typically persists as non-integrated episomal plasmids and establishes type III latency
program characterized by the expression of a
subset of viral genes i.e. six EBV nuclear antigens (EBNA-1, EBNA-2, EBNA-3A/B/C, EBNALP), three latent membrane proteins (LMP-1,
LMP-2A/B), and non-coding RNAs (EBER1/2,
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BART) including some viral microRNAs (miRNAs) are expressed [3]. The latently expressed
EBV oncoproteins exploit the intrinsic transcription programs of B-lymphocytes to achieve
immortal cell growth resulting in the altered
expression of a number of cellular genes and
miRNAs [4-6]. Therefore, LCLs have been exploited as an in vitro cell model for EBV-associated lymphoproliferative diseases [7].
We have previously shown that the EBV induced changes in the cellular transcriptome of
both mRNA and miRNA expression were reversed upon iPSC reprogramming of the LCLs
[2]. Furthermore, the down regulation of these
EBV induced transcriptomic changes suggest
significant inhibition of EBV genome transcriptional activity in the reprogrammed iPSCs,
which is essential for the EBV genome replication in the host cell, therefore iPSC reprogramming results in a gradual removal of the EBV
genomes from reprogrammed iPSCs [8, 9].
These transcriptomic events that occur during
the iPSC reprogramming of LCLs allows a
unique opportunity to better understand the
transcriptomic changes that are EBV induced in
LCLs and the changes that takes place during
iPSC reprogramming including miRNA and
mRNA interactions. In this manuscript we have
analyzed our existing mRNA and miRNA sequence data, generated from six LCLs and their
reprogrammed iPSCs, to investigate the miRNA
- mRNA interactions during these cellular
transitions.
Material and methods
A detailed description of the methodology used
in iPSC reprogramming of the six cryopreserved
LCLs, iPSC characterization, validation and
RNA sequencing of the LCLs and their reprogrammed iPSCs can be found in our previous
publication [2]. Briefly, the 6 de-identified LCLs
established from our San Antonio Family Heart
Study (SAFHS) participants from whom appropriate written consent was obtained were
reprogrammed using our highly efficient feeder
free episomal plasmid based methodology [2].
The reprogrammed iPSC lines formed flat and
compacted colonies and showed high nucleus
to cytoplasm ratios. The immunocytochemistry
(ICC) and differential gene expression analysis
showed that all of our reprogrammed iPSC lines
expressed pluripotency markers and showed
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potential to differentiate into cells of all three
germ layers (Figure 1). The six LCLs and their
well characterized and validated iPSC lines
were RNA sequenced using Illumina TruSeq
Small RNA and TruSeq mRNA sample preparation kits on the Illumina HiSeq 2500 next generation sequencing platform. Institutional Review Board and Institutional Biosafety Committee of the University of Texas Rio Grande
Valley (Edinburg, TX) approved all protocols
used in this study.
Sequence analysis
Raw fastq sequence files were generated and
demultiplexed using the Illumina CASAVA v1.8
pipeline. After pre-alignment QCs, sequences
were aligned to human genome build 19 (hg19)
and mapped to RefSeq transcripts using
StrandNGS software v3.3 (Strand Genomics
Inc.). Small RNA reads were mapped to small
RNA annotations inferred from miRbase (v20),
ensemble (e75), gtrnadb (tRNA) and UCSC
knowGene tables (piRNA) and implemented in
Strand NGS software. The aligned reads were
filtered based on default read quality matrix
and log transformation and “DESeq” normalization was applied. The known miRNAs and
mRNAs having a normalized read count (NRC) ≥
20 in all 6 LCLs or their reprogrammed iPSCs or
in both were considered expressed and selected for differential gene expression analysis.
Differential gene expression analysis
To identify differentially expressed (DE) miRNAs
and mRNAs, moderated t statistics and expression fold change analyses ware performed on
miRNA and mRNA data sets. The miRNAs and
mRNAs having moderated t statistic FDR corrected p-value ≤ 0.05 and FC absolute (FC-abs)
≥ 2.0, were considered DE.
miRNA target prediction
The miRNA target filter implemented in Ingenuity Pathway Analysis (IPA) platform, which
uses the TargetScan-Human, TarBase and
miRecords databases, was used to identify predicted and experimentally observed miRNA targets. TargetScan content in IPA uses TargetScan
algorithm predicted mRNA targets of human
miRNAs that are binned into high and moderate
confidence. TarBase content identifies experimentally demonstrated miRNA-mRNA interac-
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Figure 1. Validation of the LCL reprogrammed iPSC lines. (A) Bright filed image of LCLs and reprogrammed iPSCs,
(B) ICC analysis of the generated iPSCs showing expression of the pluripotency markers, (C) ICC analysis of the 3
embryonic germ layers differentiated from the reprogrammed iPSCs, (D, E) graphs showing differential gene expression of iPSC core pluripotency markers/genes and LCL specific markers.

tions from TarBase using miRbase identifiers.
And miRecords content uses experimentally
validated human, rat and mouse miRNA-mRNA
interactions from published literature. The
TargetScan-Human predicted mRNA targets
binned into high confidence and experimentally
observed mRNA targets from TarBase and
miRecords that were significantly DE between
LCLs and their reprogrammed iPSCs, were considered for functional analysis.
Functional annotation and gene expression
analysis
Functional annotations, upstream regulator
analysis (URA) and pathway analysis were performed on identified mRNA target gene expression data sets using IPA. Right-tailed Fisher’s
exact test p values corrected for FDR were used
to calculate enrichment significance. The direction of functional change in URA was assessed
by activation Z-score as implemented in IPA.
Further details of these methods implemented
in IPA can be found in [10].
Results and discussion
The smallRNA and mRNA sequence data generated from 6 LCLs and their validated iPSC lines
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(Figure 1) was submitted to gene expression
omnibus (GEO) archive (accession number
GSE74289). A total of 5.5 and 8.3 million small
RNA 40 bp single-end reads and 28.4 and 29.9
million mRNA 100 bp paired-end reads were
obtained for LCLs and their iPSCs, respectively.
Differentially expressed genes
To identify miRNA and mRNA interactions that
are EBV induced in LCLs and the changes that
take place during iPSC reprogramming, it was
important to first identify the miRNAs and
mRNAs that were significantly DE during the
iPSC reprogramming of LCLs. As stated in the
materials and methods section, only known
miRNAs and mRNAs having NRC ≥ 20 in all 6
samples of one or both cell types were considered expressed for differential gene expression
analysis. The moderated t-statistics and
expression fold change (FC) analysis following
the criteria, FDR corrected p-value ≤ 0.05 and
FC-abs ≥ 2.0, identified 85 miRNAs and 5,228
mRNAs that were significantly DE between
LCLs and their reprogramed iPSCs (Figure 2A,
2B; Supplementary Table 1).
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Figure 2. miRNA and mRNA differential expression analysis between LCLs and their reprogrammed iPSCs. (A) heat
map of 85 DE miRNAs, (B) heat map of 5,228 DE mRNAs, (C) correlation coefficient (r2) plots calculated for DE
miRNA and mRNA between LCLs and their reprogrammed iPSCs, (D, E) Principal component analysis (PCA) based
on DE miRNAs and mRNAs found DE between LCLs and their reprogrammed iPSCs.

The expression heat maps, correlation analysis
(correlation coefficient = 0.94 ± 0.006 at 95%
CI for LCLs and 0.96 ± 0.002 at 95% CI for
iPSCs) and the principal component analysis of
the DE miRNAs and mRNAs in six LCLs and
their reprogrammed iPSCs (Figure 2A-E) suggest discrete and uniform resetting of the miRNome and transcriptome during iPSC reprogramming.
miRNAs expressed in LCLs and their reprogrammed iPSCs: The most abundant cellular
miRNAs expressed in LCLs and showing significant down regulation in reprogrammed iPSCs
are shown in Figure 3A. Together, these 46
miRNAs accounted for ~70% of the expressed
LCLs miRNome (Figure 3C) and were highly
enriched in miRNAs (miR-155, let-7a-i, miR146a/b, mir-29a, miR-142, miR-181*, miR150, miR-10a) that have been reported to be
upregulated by EBV infection in LCLs [4, 11-13].
A total of 39 miRNAs were significantly upregulated in reprogrammed iPSCs (Figure 3B) and
these miRNAs together accounted for ~65% of
the reprogrammed iPSCs miRNome (Figure
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3C). The miRNAs associated with the human
iPSC/ESC pluripotency and maintenance (miR302a/b/c/d, miR-371/372/373, miR204, miR92b) were the most upregulated miRNA clusters/families [14, 15].
mRNAs expressed in LCLs and their reprogrammed iPSCs: A total of 2,317 mRNAs, which
together accounted for ~32% of the LCLs
expressed transcriptome, were significantly
down regulated in LCL reprogramed iPSCs
(Figure 3D). The mRNAs encoding B-cell transcription factors, major histocompatibility complex classes I and II, cell surface markers and
cellular adhesion molecules that are known to
be expressed in EBV latency III infection in LCLs
were highly enriched in these down regulated
mRNAs. A total of 2,911 mRNAs were significantly upregulated in the reprogrammed iPSCs
and they accounted for ~30% of the iPSCs
expressed transcriptome (Figure 3D). The
mRNAs/genes that are known to be involved in
stemness, pluripotency and self-renewal of
human iPSCs were highly enriched in the upregulated mRNAs. A detailed description of LCL
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Figure 3. Differentially expressed miRNA and proportion estimates of DE miRNome and DE transcriptome in LCLs
and iPSCs. (A) bar graph of significantly down regulated miRNAs, (B) bar graph of significantly up regulated miRNAs,
(C) pie graph showing proportion of DE vs total expressed miRNome in LCLs and reprogrammed iPSCs, (D) pie graph
showing the proportion of DE vs total expressed transcriptome in LCLs and reprogrammed iPSCs.

and iPSCs DE transcriptome can be found in
our previous publication [2].
In-silico miRNA target prediction and their interaction with LCL-iPSC DE transcriptome
Having established the miRNAs and mRNAs
that were upregulated by the EBV latency III
infection in LCLs and showed significant downregulation in reprogrammed iPSCs and the
miRNA and mRNAs that were significantly
upregulated in the reprogrammed iPSCs, we
next sought to determine the mRNA targets of
these DE miRNAs. First, we implemented computational miRNA target prediction using
TargetScan-Human, TarBase and miRecords
data bases in IPA. The 85 DE miRNAs mapped
to 67 mature miRNA families and 52 of these
miRNA families had targeting information available. Following the criteria that the interaction
sites were either experimentally observed and/
or predicted with high confidence, 6,008 target
mRNAs resulting into 8,215 total miRNA-mRNA
interactions were identified. 1,842 of these
32

mRNA targets were DE between LCLs and their
reprogrammed iPSCs and resulted in 2,642
miRNA-mRNA interactions (Supplementary
Table 2), 1,407 of these predicted interactions
were between miRNA-mRNA pairs that were
oppositely expressed. Since DE genes are regulated by diverse genetic and epigenetic mechanisms during iPSC reprogramming of LCLs, we
have included all DE mRNAs in the miRNA target predictions in further analysis irrespective
of the directions of miRNA-mRNA expressions.
LCL specific miRNA-mRNA interactions: The 27
miRNA families that were expressed in LCLs
but significantly down-regulated upon reprogramming, were predicted to target 1,141
mRNAs that were DE between LCLs and their
reprogrammed iPSCs (resulting in 1,425 miRNA-mRNA interactions). Of these miRNA-mRNA
interactions, 244 were experimentally observed
in other studies (Supplementary Table 2). To
further validate our findings, we queried our
unique mRNA targets identified by LCL specific
miRNA-mRNA interactions against high confiAm J Stem Cells 2019;8(2):28-37
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dence 3’ UTR miRNA-interaction sites identified
by Argonaute 2 (Ago-2) based PER-CLIP analysis of LCLs in a previously published study
Skalsky et al., [4]. Of the 1,141 mRNA targets,
324 (~29%) were also among the mRNA targets
identified by Ago-2 based PER-CLIP analysis of
the LCLs, suggesting a high concordance
between the two studies. Next, we focused on
miR-155, the most abundant cellular miRNA in
LCLs. The EBV encoded EBNA2, EBNALP and
LMP1-acivated NF-κB subunit upregulates miR155 in LCLs and its expression is essential for
LCL survival in in vitro cultures [6, 16].
Expression of miR-155 is implicated in a number of B-cell malignancies and plays an important oncogenic role in herpesvirus biology as
both Kaposi’s sarcoma-associated herpesvirus
(KSHV) and Marek’s disease virus (MDV)
encode functional miR-155 analogs [4]. We
have identified 77 DE mRNAs which were the
predicted targets of miR-155 in our data set
and 55 of these targets were experimentally
observed in previous studies in IPA (Supplementary Table 2). The functional annotation
and gene expression analysis of identified miR155 targets (77 DE mRNAs) showed very high
enrichment in Cancer (74 molecules; p-value
range 1.88E-03 - 1.48E-08) and in cellular
growth and proliferation functional categories
(36 molecules; p-value range 1.81E-03 - 7.01E09). An upstream regulator analysis of the miR155 targets, predicted activation of SOX2,
SYVN1 and ESR1 (activation z-score ≥ 2.0) regulated genes and inhibition of TAL1, TNFSF11
and TP53 (activation z-score ≤ -2.0) regulated
genes, which suggest that miR-155 down regulation promotes LCL to iPSC reprogramming.
miRNA-mRNA interactions of miRNAs upregulated in iPSCs: The 25 miRNA families which
were significantly upregulated in reprogrammed
iPSCs, were predicted to target 1,002 DE
mRNAs and resulted in 1,217 total miRNAmRNA interactions. About 14% of these interactions were experimentally observed in previous
studies (Supplementary Table 2). The human
embryonic stem cell (ESCs) and iPSCs express
a unique set of miRNAs with the majority transcribed from two genomic loci, the miR-302
cluster encoding miR-302a/b/c/d and miR371-373 cluster encoding miR-371, miR-372
and miR-373 [17, 18]. The miR-302 and miR371-373 clusters and a highly related miRNA,
miR-92b accounted for the majority (~67%) of
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the DE miRNome in our reprogrammed iPSCs
and were predicted to target 143 DE mRNAs.
The functional annotation and gene expression
analysis of these 143 predicted targets showed
high enrichment in cell death and survival (70
molecules; p-value range 4.83E-04 - 3.62E09), cell cycle (43 molecules; p-value range
4.87E-04 - 5.14E-09), cellular assembly and
organization (37 molecules; p-value range
4.08E-04 - 1.28E-08), and cellular development (62 molecules; p-value range 4.95E-04 3.81E-09), which supports previous findings
and the role of these miRNA clusters in self
renewal, cell proliferation and cell cycle progression of human ESC and iPSCs [18, 19]. The
upstream regulator prediction of the miR-302
and miR-371-373 clusters and miR-92b mRNA
targets showed inhibition (activation z-score ≤
-2.0) of several cytokines (IL4, CSF2, CD40LG,
IL2, IL18, IL7, IFNB1, IFNG and OSM), transcription regulators (STAT1, RUNX3, XBP1, IRF1,
EGR1 and PDX1) and the growth factor BMP4,
which suggests the role of these miRNA clusters in inhibiting the LCL specific pathways and
pathways involved in stem cell differentiation.
Role of DE miRNAs in the regulation of key LCL
and iPSC canonical pathways
Further, we explored the miRNA-mRNA interactions in key LCL and iPSC canonical pathways.
B cell receptors signaling: Previous studies
have shown that latently expressed EBV oncoproteins mimic B-cell receptor (BCR) signaling to
activate NF-κB, JNK, and MAPK pathways and
support rapid growth and survival of latently
infected B-cells/LCLs [3, 5] and these pathways are significantly inhibited upon reprogramming of LCLs into iPSCs [2]. The miRNA
target prediction analysis identified 36 DE
mRNAs associated with BCR signaling pathways, which were the predicted targets for 34
DE miRNA families, resulting in a total of 61
miRNA-mRNA interactions potentially involved
in the regulation of BCR signaling. The most significant 53 miRNA-mRNA interactions, out of
which 24 showed opposite expression of miRNA
and their target mRNA, are shown in Figure 4.
Human ESC pluripotency: We have shown previously that LCL reprogrammed iPSCs have
similar properties both in self renewal and differentiation capacity to human ESCs [2]; there-
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Figure 4. miRNA-mRNA network showing potential miRNA-mRNA interactions in B-cell receptor signaling.

fore next we explored miRNA-mRNA interactions between DE mRNA associated with
human ESC pluripotency pathways. A total of
46 interactions between 24 miRNA families
and 27 DE mRNAs were identified (Figure 5).
About 50% of these miRNA-mRNA interactions
showed opposite expression pairing of the miRNAs and their targets.
Conclusions
We identified 85 miRNAs that were DE between
LCLs and their reprogrammed iPSCs. These 85
DE miRNAs mapped to 67 mature miRNA families. The 1,842 mRNAs that were DE between
LCLs and their reprogrammed iPSCs were predicted (with high confidence) to be the potential
target of the 52 mature miRNA families identified in this study. A total of 2,642 miRNA-mRNA
interactions were identified between LCLs and
iPSCs DE miRNome and transcriptome which
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suggests a significant role of miRNA mediated
regulation of transcriptional changes that takes
place during reprogramming of LCLs into iPSCs.
There are several potential limitations of this
study. For example, only a small percentage of
these miRNA-mRNA interactions are experimentally observed, and the majority of the predicted interactions are yet to be confirmed, only
about half of the interactions were between
oppositely expressed miRNA-mRNA pairs, and
diverse genetic and epigenetic mechanisms
are involved in transcriptional regulation during
iPSC reprogramming of LCLs, which complicates the identification of potential miRNAs targets. However, this study provides a comprehensive list of miRNA-mRNA interactions predicted with high confidence using genome wide
DE miRNome and transcriptome of LCLs and
their reprogrammed iPSCs. This data is relevant to better understand EBV biology in LCLs
and in EBV related lymphomas, as well as
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Figure 5. miRNA-mRNA network showing potential miRNA-mRNA interactions in human embryonic stem cell pluripotency pathways.
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understanding the miRNA mediated transcriptomic regulation of iPSC self-renewal and
pluripotency.
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